Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset

 Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the biotech’s lead asset, telitacicept.

Analyst Anupam Rama argued that telitacicept, marketed in China by Vor’s (VOR) partner RemeGen (REGMF) for autoimmune diseases such as myasthenia gravis, has been “highly derisked” for multiple indications.

With global late-stage studies for the drug underway, including for MG and primary Sjögren’s disease ((pSD)), Rama noted that telitacicept for each of the indications targeted by Vor Bio (VOR) could generate blockbuster peak sales in the U.S. alone.

The analyst noted that there is a sizable valuation disconnect between VOR shares and telitacicept’s probability-adjusted value in MG and pSD.

“As the known late-stage data from China in both indications are better appreciated and there is progress in the global studies, we see the potential for VOR shares to grind higher,” he added.

https://www.msn.com/en-us/money/companies/vor-bio-spikes-as-jp-morgan-starts-at-overweight-on-lead-asset/ar-AA1S1mCj